Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. 

We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Janus Henderson Investors

Franklin Templeton

Access Biotechnology

Atlas Venture

Boxer Capital

Canaan Partners

T. Rowe Price

Viking Global Investors

Perceptive Advisors

RA Capital Management

Day One Biopharmaceuticals

Molly’s advice for others going through a pediatric low-grade glioma (#pLGG) journey is to keep a list of questions to ask the doctor — even the small things. To hear more stories from people living with pLGG and tips for navigating a challenging diagnosis, visit: https://lnkd.in/eDtwpMUz

#RethinkpLGG

Today, we celebrate and support raising awareness for #RareDiseaseDay! More than 300 million people around the world live with a rare disease. Though considered a rare #cancer, pediatric low-grade glioma (pLGG) accounts for approximately 30% of all childhood brain tumors. There is a considerable need for increased visibility and awareness for #pLGG and all rare diseases. 

Head of R&D and co-founder Samuel Blackman shares the Day One journey to reshape #pediatriccancer drug development in this article for the Pediatric Cancer Research Foundation’s Profectus blog, Turning “One Day” into “Day One”: https://bit.ly/3URbMzF

Our co-founder and Head of R&D, Samuel Blackman, recently sat down with Michael Pietrack of The Pharmaverse Podcast to discuss how Sam’s expedition to the base camp of Mount Everest influenced his #leadership philosophy. Sam speaks to the power of vulnerability and camaraderie and how these universal lessons can positively impact the compassionate care provided to young patients and their families. Watch the full episode here: https://lnkd.in/epZpSG3C 

Today, on #NationalCaregiversDay, we spotlight the selfless care, love and support #caregivers provide to those who need it most. Remember to thank a #caregiver, not only today, but every day, for helping our loved ones live better lives.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue					383K -
gross profit					-383K -
selling and marketing expenses					-383K -
general and administrative expenses	1.01M -	4.68M 365.41%	29.16M 522.79%	61.29M 110.20%	75.54M 23.25%
selling general and administrative expenses	1.01M -	4.68M 365.41%	29.16M 522.79%	61.29M 110.20%	75.16M 22.63%
research and development expenses	13.90M -	9.10M 34.53%	43.58M 378.95%	85.62M 96.44%	130.52M 52.45%
other expenses	-2K -	-31K 1,450%	-15K 51.61%	-18K 20%
cost and expenses	14.90M -	13.78M 7.53%	72.74M 427.81%	146.91M 101.96%	206.06M 40.27%
operating expenses	14.90M -	13.78M 7.53%	72.74M 427.81%	146.91M 101.96%	205.68M 40.01%
interest expense	2.08M -	30K 98.56%	4K 86.67%	4.75M 118,550%
ebitda	-14.91M -	-13.66M 8.38%	-72.74M 432.60%	-146.91M 101.96%	-205.68M 40.01%
operating income	-14.90M -	-13.78M 7.53%	-72.74M 427.81%	-146.91M 101.96%	-206.06M 40.27%
depreciation and amortization	-2K -	124K 6,300%	199K 60.48%	531K 166.83%	383K 27.87%
total other income expenses net	-2.08M -	-30.06M 1,345.94%	-11K 99.96%	4.73M 43,081.82%	17.15M 262.67%
income before tax	-16.98M -	-43.84M 158.14%	-72.75M 65.94%	-142.18M 95.43%	-188.92M 32.87%
income tax expense	-2.27M -	-3.34M 46.81%	-2.31M 30.72%	-10.01M 332.74%
net income	-14.71M -	-40.51M 175.34%	-70.44M 73.91%	-132.18M 87.64%	-188.92M 42.93%
weighted average shs out	42.03M -	42.03M 0%	36.96M 12.06%	65.47M 77.13%	79.77M 21.85%
weighted average shs out dil	42.03M -	42.03M 0%	36.96M 12.06%	65.47M 77.13%	79.77M 21.85%
eps	-0.35 -	-0.96 174.29%	-1.91 98.96%	-2.02 5.76%	-2.37 17.33%
epsdiluted	-0.35 -	-0.96 174.29%	-1.91 98.96%	-2.02 5.76%	-2.37 17.33%

COM:DAYONEBIO

Day One Bio

Last Close

13.34

22/11 21:00

Market Cap

1.29B

Beta: -

Volume Today

591.56K

Avg: -

Preview